Related Experiment Video
Updated: May 22, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Continuous infusion in haemophilia: current practice in Europe
A Batorova1, P Holme, A Gringeri
1Department of Haematology and Transfusion Medicine, National Haemophilia Centre, University Hospital, Bratislava, Slovakia. batorova@hotmail.sk
Continuous infusion (CI) of factor VIII (FVIII) is safe and effective for haemophilia patients, with no increased risk of inhibitor development in severe cases. This study evaluated current European practices and found CI to be a reliable treatment option.
Area of Science:
- Hematology
- Pharmacology
- Clinical Medicine
Background:
- Continuous infusion (CI) of factor VIII (FVIII) is a common replacement therapy for haemophilia.
- Concerns exist regarding a potential association between CI and the development of inhibitors.
Purpose of the Study:
- To investigate current European practices for CI in haemophilia treatment.
- To determine the actual incidence of inhibitor development associated with CI therapy.
Main Methods:
- A cross-sectional study involving 22 Comprehensive Care Centres (CCCs) in Europe.
- Evaluation of CI techniques, treatment protocols, efficacy, safety, and complications, including inhibitor development.
- Analysis of data from 1079 CI treatments in 742 patients.
Main Results:
- CI was haemostatically effective with a low incidence of complications (1.8% postoperative bleeding).
- Phlebitis was observed in 2-11% of CI treatments at six centres.
- Only 1.2% of patients developed inhibitors; analysis revealed confounding factors in inhibitor development.
Conclusions:
- CI treatment is effective and safe for haemophilia patients, not increasing inhibitor risk in severe haemophilia.
- Previous reports suggesting CI increases inhibitor risk are not confirmed in this large cohort.
- Inhibitor risk in mild haemophilia requires further investigation due to potential confounding factors.
More Related Videos
08:01The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
Published on: February 27, 2026
09:38A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
One-Compartment Model: IV Infusion
The one-compartment model for IV infusion uses mathematical equations to describe the rate of change in drug quantity in the body. At steady-state or infusion equilibrium, the drug input...
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration